Anova Marks 1,500th Prostate Cancer Patient Treated with the Accuray CyberKnife® System

SUNNYVALE, Calif., June 16, 2017 /PRNewswire/ -- In honor of Father's Day, Accuray Incorporated (NASDAQ: ARAY) joins Anova Cancer Care in recognizing the center's commitment to providing the most advanced treatments available to men with prostate cancer, many of whom are fathers. The center, located in Lone Tree, Colorado, has treated its 1,500th prostate cancer patient using the CyberKnife® System—an advanced radiation therapy device designed to deliver stereotactic body radiation therapy (SBRT). SBRT is a highly precise form of radiation therapy which maximizes dose to the tumor and minimizes dose to surrounding healthy tissue.

According to the American Cancer Society, more than 161,000 men will be diagnosed with prostate cancer in 2017. It's important for men to take action to improve their health, including learning about medical conditions which specifically impact them, like prostate cancer, and options for managing the disease. This Father's Day, June 18, 2017, men and their families can learn about prostate cancer at rallies held by:

• ZERO – The End of Prostate Cancer
• The Prostate Health Education Network (PHEN)

The prostate gland can move unpredictably throughout the course of treatment because of normal patient bodily functions – such as filling of the bladder, gas in the bowel, or even patient movement during the procedure – making the ability to track, detect and correct for motion critically important. Unlike any other radiation treatment, the CyberKnife System continually tracks and automatically corrects the beam for movement of the prostate in real-time throughout the entire treatment session. Published data reinforce that CyberKnife prostate SBRT is effective, with minimal side effects and impact on quality of life during and after treatment, important considerations for men diagnosed with prostate cancer.

Additional Information About CyberKnife Prostate SBRT

• Treatment with the CyberKnife System is non-invasive (no surgery involved) and is completed in 4-5 treatment sessions, over the course of one or two weeks. Conventional radiation therapy typically requires 30-40 treatment sessions, over the course of several weeks;
• CyberKnife treatment accuracy is achievable without the need for invasive rectal balloons or spacers to spare the rectal wall;
• The system can precisely target tumors and as a result, may provide a safe radiation treatment option even for some previously irradiated patients;
• SBRT increases patient satisfaction by reducing discomfort and scheduling inconvenience versus conventional radiation treatments.

Quotes
Tim B.: "When I was diagnosed with prostate cancer I immediately imagined the worst. I have several grandchildren who I want to spend time with as they grow up. I discussed treatment options with my urologist and radiation oncologist and together, we decided that treatment with the CyberKnife® System was the best option for me. I liked that the technology is really precise so the radiation would be targeting my prostate and my risk for side effects would be minimized. And the convenience of only needing five days of treatment was a real bonus."

Lee K. McNeely, M.D., Radiation Oncologist at Anova Cancer Care: "Anova Cancer Care is a busy radiation therapy center, so it's important that we have technology we trust to provide our patients with the best possible treatment option. We use the CyberKnife for prostate cancer because it offers distinct advantages when treating this disease, most notably it's the only system available with the ability to track movement of the prostate and automatically adjust the radiation beam during treatment. The CyberKnife System's accuracy is sub-millimeter, enabling my colleagues and me to treat the disease with unparalleled preservation of healthy tissue and provide substantial quality of life and lifestyle benefits to patients."

Stanley H. Galansky, MD, FACS, FAAP, Urologist at Urology Associates: "Urology Associates offers a range of treatment options for prostate cancer, including the CyberKnife, which we administer on an out-patient basis at Anova Cancer Care. We partnered with Anova to offer our patients this option because we believe it effectively manages the cancer with considerably fewer side effects than traditional cancer treatments. With the CyberKnife System, we treat patients in 5 sessions and it's less expensive for the patient and their insurance company. Most importantly, the system has provided quality outcomes for our patients."

Joshua H. Levine, President and Chief Executive Officer of Accuray: "We commend Dr. McNeely and the Anova Cancer Care team on their dedication to improving the lives of their patients. We appreciate our continued partnership and are honored they have selected the CyberKnife technology to treat so many of their low- to intermediate-risk prostate cancer patients. The CyberKnife System is continuing to demonstrate its position as the radiation treatment of choice for more and more physicians and patients. It offers a convenient, non-invasive approach which precisely targets the prostate cancer with minimal disruption to patients' daily lives."

Important Safety Information 
For Important Safety Information please refer to http://www.accuray.com/safety-statement

About Accuray 
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
[email protected]

Jane Hauser
MSLGROUP
+1 (781) 684-0770
[email protected]

SOURCE Accuray Incorporated